Clinical evidence from ER‐positive tumours showed that most samples with TP53 wild type (WT) were resistant to chemotherapy, while ER‐negative subtypes are more sensitive to chemotherapy due to TP53 mutations.49 This evidence concerns the gene TP53 and neoplasm.